REVIEW ARTICLE
Oncology
doi: 10.25005/2074-0581-2026-28-3-782-790
CARDIOTOXICITY OF CHEMOTHERAPEUTIC AGENTS

K.Z. URAKOV, M.A. SHONAZAROVA, G.KH. KUVATZODA, G.B. KHODZHIEVA

Department of Internal Diseases No. 3, Avicenna Tajik State Medical University, Dushanbe, Republic of Tajikistan

Cardiotoxicity is the ability of a medicinal product to induce adverse structural and/or functional changes in the cardiovascular system. The introduction

of modern chemotherapy protocols has been associated with an increasing incidence of cardiotoxic effects and a broad time range of their manifestation, which may occur both during the acute phase of treatment and months or even years after its completion. This review systematizes the available literature on chemotherapeutic agents associated with cardiotoxicity.

The literature search used the PubMed, eLibrary, and CyberLeninka electronic databases with the following keywords: “acute leukemia”, “chronic

leukemia”, “chemotherapeutic agents”, “cardiotoxicity”, “early and long-term effects”, and “endothelial dysfunction”. We included studies published

between 2015 and 2025. The inclusion criteria included publications describing myocardial and vascular tissue injury associated with drug classes such

as anthracyclines, targeted monoclonal antibodies, and tyrosine kinase inhibitors. Studies focusing predominantly on toxic effects involving other organs

and systems were excluded.

The findings of numerous studies confirm that chemotherapy-induced cardiotoxicity remains an important global concern in cardio-oncology. Early

detection of preclinical and clinical markers of cardiac injury may help optimize anticancer treatment, including dose adjustment, selection of agents with

a more favorable cardiotoxicity profile, and development of new combination treatment regimens.

Keywords: Acute leukemia, chronic leukemia, chemotherapeutic agents, cardiotoxicity, early and long-term effects, endothelial dysfunction.

Download file:

References
  1. Thomas SA. Chemotherapy agents that cause cardiotoxicity. US Pharm. 2017;42(9): HS24-HS33.
  2. Leong DP, Cosman T, Alhussein MM, Tyagi NK, Barron CC, Wright D, et al. Safety of continuing trastuzumab despite mild cardiotoxicity: A phase I trial. J Am Coll Cardiol CardioOnc. 2019;1(1):1-10. https://doi.org/10.1016/j.jaccao.2019.06.004
  3. Kulieva AA, Emelina EI, Gendlin GE, Nikitin IG, Zyryanov SK, Varentsov SI, i dr. Serdechno-sosudistye oslozhneniya terapii ingibitorami kontrol'nykh tochek immuniteta [Cardiovascular complications of therapy with immune checkpoint inhibitors]. Kachestvennaya klinicheskaya praktika. 2019;1:55-65.
  4. Anderzhanova LKh, Rybalko NA, Shatskiy MA, Tikhomirova EA, Myakova NV. Serdechnaya nedostatochnost' kak proyavlenie ostrogo limfoblastnogo leykoza [Heart failure as a manifestation of acute lymphoblastic leukemia]. Voprosy gematologii/onkologii i immunopatologii v pediatrii. 2023;22(1):147-51. https:// doi.org/10.24287/1726-1708-2023-22-1-147-151
  5. Emelina EI, Gendlin GE, Nikitin IG. Antitromboticheskaya terapiya u patsientov so zlokachestvennymi limfoproliferativnymi zabolevaniyami, poluchayushchikh ibrutinib [Antithrombotic therapy in patients with malignant lymphoproliferative diseases receiving ibrutinib]. Klinicheskaya onkogematologiya. 2019;12(4):449- 60
  6. Chazova IE, Tyulyandin SA, Vitsenya MV, Avchininnikov AG, Poltavskaya MG, Gilyarov MYu, i dr. Rukovodstvo po diagnostike, profilaktike i lecheniyu serdechno-sosudistykh oslozhneniy protivoopukholevoy terapii [Guidelines for the diagnosis, prevention and treatment of cardiovascular complications of antitumor therapy]. Sistemnye gipertenzii. 2017;14(3):6-20.
  7. Gendlin GE, Emelina EI, Nikitin IG, Vasyuk YuA. Sovremennye vzglyady na kardiotoksichnost' khimioterapii onkologicheskikh zabolevaniy, vklyuchayushchey antratsiklinovye antibiotiki [A modern view on the cardiotoxicity of cancer chemotherapy, including anthracycline antibiotics]. Rossiyskiy kardiologicheskiy zhurnal. 2017;3:145-54.
  8. Romitan DM, Rădulescu D, Berindan-Neagoe I, Stoicescu L, Grosu A, Rădulescu L, et al. Cardiomyopathies and arrhythmias induced by cancer therapies. Biomedicines. 2020;8(11):496. https://doi.org/10.3390/biomedicines8110496
  9. Avirup G, Mohamed HD, Tracy EW, John CB, Farrukh TA. Ventricular arrhythmias following ibrutinib initiation for cancer immunotherapy. J Am Coll Cardiol. 2018;72(6):697-8. https://doi.org/10.1016/j.jacc.2018.06.002
  10. Matylda M, Feilong W. Burden of cardiac arrhythmias in patients with anthracycline-related cardiomyopathy. JACC Clin Electrophysiol. 2017;3(2):139- 50. https://doi.org/10.1016/j.jacep.2016.08.009
  11. Kang Y, Assuncao BL, Denduluri S, McCurdy S, Luger S, Lefebvre B, et al. Symptomatic heart failure in acute leukemia patients treated with anthracyclines. JACC CardioOncol. 2019;1(2):208-17. https://doi.org/10.1016/j. jaccao.2019.10.008
  12. Fashafsha ZZ, Mesitskaya DF, Kopylov FYu, Salpagarova ZK, Bykova AA. Diagnosticheskie aspekty serdechno-sosudistykh oslozhneniy khimioterapii [Diagnostic aspects of cardiovascular complications of chemotherapy]. Kardiologiya i serdechno-sosudistaya khirurgiya. 2022;15(1):40-5.
  13. Baron T, Berglund L, Hedin EM, Flachskampf FA. Test-retest reliability of new and conventional echocardiographic parameters of left ventricular systolic function. Clin Res Cardiol. 2019;108(4):355-65. https://doi.org/10.1007/s00392-018- 1363-7
  14. Larsson K, Mattsson M, Ebrahim F, Glimelius I, Höglund M. High prevalence and incidence of cardiovascular disease in chronic lymphocytic leukaemia: A nationwide population-based study. Br J Haematol. 2020;190(4):e245-e248. https://doi.org/10.1111/bjh.16859
  15. van Nimwegen FA, Ntentas G, Darby SC, Schaapveld M, Hauptmann M, Lugtenburg PJ, et al. Risk of heart failure in survivors of Hodgkin lymphoma: Effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129(16):2257- 65. https://doi.org/10.1182/blood-2016-09-740332
  16. Refaie MMM, Shehata S, El-Hussieny M, Abdelraheem WM, Bayoumi AMA. Role of ATP-sensitive potassium channel (KATP) and eNOS in mediating the protective effect of nicorandil in cyclophosphamide-induced cardiotoxicity. Cardiovasc Toxicol. 2020;20(1):71-81. https://doi.org/10.1007/s12012-019-09535-8
  17. Deac AL, Burz CC, Bocsan IC, Buzoianu AD. Fluoropyrimidine-induced cardiotoxicity. World J Clin Oncol. 2020;11(12):1008-17. https://doi.org/10.5306/ wjco.v11.i12.1008
  18. Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, et al. 5-fluorouracil and cardiotoxicity: A review. Ther Adv Med Oncol. 2018;10:1758835918780140. https://doi.org/10.1177/1758835918780140
  19. Wang Y, Ma Q, Zhang S, Liu H, Zhao B, Du B, et al. Digoxin enhances the anticancer effect on non-small cell lung cancer while reducing the cardiotoxicity of adriamycin. Front Pharmacol. 2020;11:186. https://doi.org/10.3389/ fphar.2020.00186
  20. Liu Y, Zhou L, Chen Y, Liao B, Ye D, Wang K, Li H. Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: A systematic review and meta-analysis. BMC Urol. 2019;19(1):49. https://doi. org/10.1186/s12894-019-0481-5
  21. Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol. 2018;2:13. https://doi.org/10.1038/s41698- 018-0056-z
  22. Marvel FA, Whelton SP, Blumenthal RS. A Cardio-oncology cardiovascular prevention framework. JACC CardioOncol. 2019;1(2):252-5. https://doi. org/10.1016/j.jaccao.2019.11.012
  23. Bottinor WJ, Shuey MM, Manouchehri A, Farber-Eger EH, Xu M, Nair D, et al. Renin-angiotensin-aldosterone system modulates blood pressure response during vascular endothelial growth factor receptor inhibition. JACC CardioOncol. 2019;1(1):14-23. https://doi.org/10.1016/j.jaccao.2019.07.002
  24. Baranova OYu, Shirin AD. Sovremennyy vzglyad na patogenez, diagnostiku i lechenie otdel'nykh redkikh variantov ostrykh leykozov [A modern perspective on the pathogenesis, diagnosis, and treatment of certain rare variants of acute leukemias]. Klinicheskaya onkogematologiya. 2022;15(4):307-26. http://doi. org/10.21320/2500-2139-2022-15-4-307-326
  25. Kushnaryova EA, Moiseeva OM. Miokardity, assotsiirovannye s terapiey ingibitorami kontrol'nykh tochek: sistematicheskiy analizk linicheskikh sluchaev [Myocarditis associated with checkpoint inhibitor therapy: A systematic analysis of clinical cases]. Rossiyskiy kardiologicheskiy zhurnal. 2020;25(11):3910. https://doi.org/10.15829/29/1560-4071-2020-3910
  26. Ganatra S, Neilan TG. Immune checkpoint inhibitor-associated myocarditis. Oncologist. 2018;23(8):879-86. https://doi.org/10.1634/theoncologist.2018-0130
  27. Li VW, Liu AP, So EK, Ho KK, Yau JP, Cheuk DK, et al. Two- and three-dimensional myocardial strain imaging in the interrogation of sex differences in cardiac mechanics of long-term survivors of childhood cancers. Int J Cardiovasc Imaging. 2019;35(6):999-1007. https://doi.org/10.1007/s10554-019-01573-1
  28. Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, Lunde IG, Wakimoto H, Smith AM, et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation. 2019;140(1):31-41. https://doi.org/10.1161/ CIRCULATIONAHA.118.037934
  29. Mohanty BD, Mohanty S, Hussain Y, Padmaraju C, Aggarwal S, Gospin R, Yu AF. Management of ischemic coronary disease in patients receiving chemotherapy: An uncharted clinical challenge. Future Cardiol. 2017;13(3):247-57. https://doi. org/10.2217/fca-2017-0002
  30. Ishekova MYu, Kholmatova KK, Martyushov SI. Ostryy koronarnyy sindrom i vpervye diagnostirovannyy ostryy limfoblastnyy leykoz [Acute coronary syndrome and newly diagnosed acute lymphoblastic leukemia]. Trudnyy patsient. 2020;18(8):61-5.
  31. Luo Z, Cheng J, Wang Y Cardiac infiltration as the first manifestation of acute lymphoblastic leukemia: A systematic review. Front Oncol. 2022;12:805981. https://doi.org/10.3389/fonc.2022.805981
  32. Prenner SB, Franken AA, Murphy IG, Mikati IA. Rapid reversal of focal left ventricular hypertrophy and systolic dysfunction resulting from myocardial infiltration by acute lymphoblastic leukemia. Circulation. 2016;133(7):678-9. https://doi.org/10.1161/CIRCULATIONAHA.115.020035
  33. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20):e618-e651. https://doi.org/10.1161/CIR.0000000000000617. Erratum in: Circulation. 2018;138(20):e652. https://doi.org/10.1161/ CIR.0000000000000632
  34. Militaru AG, Zus S, Cîmpean AM, Iurciuc S, Matusz PL, Iurciuc M, et al. Early diagnosis of cardiotoxicity in patients undergoing chemotherapy for acute lymphoblastic leukemia. AntiCancer Research. 2019;39:3255-64. https://doi. org/10.21873/anticanres.13467
  35. Valiev TT, Shervashidze MA, Belysheva TS. Otsenka toksichnosti terapii ostrogo limfoblastnogo leykoza po protokolu ALLIC-BFM 2002 [Assessment of the toxicity of acute lymphoblastic leukemia therapy according to the ALLIS-BFM protocol 2002]. Onkogematologiya. 2022;17(3):137-59.
  36. Bohdan M, Kowalczys A, Mickiewicz A, Gruchała M, Lewicka E. Cancer therapyrelated cardiovascular complications in clinical practice: Current perspectives. J Clin Med. 2021;10(8):1647. https://doi.org/10.3390/jcm10081647
  37. Calvillo-Argüelles O, Schoffel A, Capo-Chichi JM, Abdel-Qadir H, Schuh A, Carrillo-Estrada M, et al. Cardiovascular disease among patients with AML and CHIP-related mutations. JACC CardioOncol. 2022;4(1):38-49. https://doi. org/10.1016/j.jaccao.2021.11.008
  38. Xiao W, Ma L, Shang Y, Yang F, Tan Y, Chen G, et al. Cardiac-related lesions in newly diagnosed patients with acute leukemia: A Chinese population-based realworld study. Front Med (Lausanne). 2022;9:844350. https://doi.org/10.3389/ fmed.2022.844350
  39. Mulder FI, Candeloro M, Kamphuisen PW, Di Nisio M, Bossuyt PM, Guman N, et al; CAT-prediction collaborators. The Khorana score for prediction of venous thromboembolism in cancer patients: A systematic review and metaanalysis. Haematologica. 2019;104(6):1277-87. https://doi.org/10.3324/ haematol.2018.209114
  40. Poltavskaya MG, Emelina EI, Avdeev YuV, Gendlin GE, Paramonova GN. Porazheniya klapanov serdtsa vsledstvie luchevoyt erapii zlokachestvennykh novoobrazovaniy [Damage to the heart valves due to radiation therapy of malignant neoplasms]. Kardiologiya. 2019;59(2):56-68. https://doi. org/10.18087/cardio.2656
  41. Muratov RM, Babenko SI, Sachkov AS, Soboleva NN, Andrianova EA. Postluchevoe porazhenie klapanov serdtsa. Printsipy diagnostiki i rezul'taty lecheniya [Postradiation damage to the heart valves. The principle of diagnosis and treatment results]. Kardiologiya. 2019;59(3):36-42. http://doi.org/10.18087/2019.10239
  42. Cheng F, Xu Q, Li Q, Cui Z, Li W, Zeng F. Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies. Front Oncol. 2023;13:1113462. https://doi. org/10.3389/fonc.2023.1113462
  43. Zafar MR, Mustafa SF, Miller TW, Alkhawlani T, Sharma UC. Outcomes after transcatheter aortic valve replacement in cancer survivors with prior chest radiation therapy: A systematic review and meta-analysis. Cardiooncology. 2020;6:8. https://doi.org/10.1186/s40959-020-00062-y
  44. Chazova IE, Arkhipova OA, Martynyuk TV. Legochnaya arterial'naya gipertenziya v Rossii. Analiz shestiletnego nablyudeniya po dannym Natsional'nogo registra [Pulmonary arterial hypertension in Russia. Analysis of a six-year follow-up based on data from the National Register]. Terapevticheskiy arkhiv.2019;1:24-31.
  45. Sárközy M, Varga Z, Gáspár R, Szűcs G, Kovács MG, Kovács ZZA, et al. Pathomechanisms and therapeutic opportunities in radiation-induced heart disease: From bench to bedside. Clin Res Cardiol. 2021;110(4):507-31. https:// doi.org/10.1007/s00392-021-01809-y
  46. Heck SL, Mecinaj A, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): Extended follow-up of a 2×2 factorial, randomized, placebocontrolled, double-blind clinical trial of Candesartan and Metoprolol. Circulation. 2021;143(25):2431-40. https://doi.org/10.1161/CIRCULATIONAHA.121.054698
  47. Taunk NK, Haffty BG, Kostis JB, Goyal S. Radiation-induced heart disease: Pathologic abnormalities and putative mechanisms. Front Oncol. 2015;5:39. https://doi.org/10.3389/fonc.2015.00039
  48. Padegimas A, Clasen S, Ky B. Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity. Trends Cardiovasc Med. 2020;30(1):22-8. https://doi.org/10.1016/j.tcm.2019.01.006
  49. Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, et al. cardiooncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. Circulation. 2019;139(21):e997-e1012. https://doi.org/10.1161/ CIR.0000000000000679
  50. Vitsenya MV, Potekhina AV, Gavryushina SV, Ibragimova NM, Masenko VP, Ageev FT. Profilaktika i lechenie disfunktsii levogo zheludochka i serdechnoy nedostatochnosti, svyazannykh s protivoopukholevoy terapiey: vozmozhnosti i perspektivy [Prevention and treatment of left ventricular dysfunction and heart failure associated with antitumor therapy: Opportunities and prospects]. Effektivnaya farmakoterapiya. 2020;16(18):108-20. http://doi.org/10.33978-2307- 3586-2020-16-18-108-120

Authors' information:

Urakov Komron Zokirovich,
Candidate of Medical Sciences, Associate Professor, Head of the Department of Internal Diseases No. 3, Avicenna Tajik State Medical University
ORCID ID: 0000-0002-1027-7834
SPIN: 3301-7051
Author ID: 1029754
E-mail: komron_med.83@mail.ru

Shonazarova Mardzhona Ayniddinovna,
Applicant of the Department of Internal Diseases No. 3, Avicenna Tajik State Medical University
ORCID ID: 000-0002-2807-088X
SPIN: 7967-4018
Author ID: 1275876
E-mail: marjoshon@mail.ru

Kuvatzoda Gulafzobonu Khayrutdin,
Postgraduate Student of the Department of Internal Diseases No. 3, Avicenna Tajik State Medical University
ORCID ID: 0009-0004-4657-375X
E-mail: gulafzo.quvatova@icloud.com

Khodzhieva Gulnora Boboevna,
Candidate of Medical Sciences, Associate Professor of the Department of Internal Diseases No. 3, Avicenna Tajik State Medical University
ORCID ID: 0000-0001-6575-3909
SPIN: 7847-2628
Author ID: 1029746

Information about support in the form of grants, equipment, medications

The authors did not receive financial support from manufacturers of medicines and medical equipment

Conflicts of interest: No conflict

Address for correspondence:

Urakov Komron Zokirovich
Candidate of Medical Sciences, Associate Professor, Head of the Department of Internal Diseases No. 3, Avicenna Tajik State Medical University

734026, Republic of Tajikistan, Dushanbe, Sino str., 29-31

Tel.: +992 (900) 004666

E-mail: komron_med.83@mail.ru


This work is licensed under a Creative Commons Attribution 4.0 International License.

Materials on the topic:
  1. CURRENT PERSPECTIVES ON SUPPORTIVE CARE IN ONCOLOGY
  2. COMPREHENSIVE TREATMENT OF LOCALLY ADVANCED AND METASTATIC GASTRIC CANCER: THE ROLE OF NEOADJUVANT INTRA-ARTERIAL CHEMOTHERAPY
  3. IMMUNOLOGICAL PROFILE OF SEROUS OVARIAN CARCINOMA AND DUCTAL BREAST CARCINOMA
  4. CLINICAL AND MORPHOLOGICAL FEATURES AND CYTOKINE STATUS ASSESSMENT IN THYROID CANCER
  5. EVALUATION OF THE EFFICIENCY OF COMBINED TREATMENT OF PATIENTS WITH BONE METASTASES FROM KIDNEY AND PROSTATE CANCER USING SYSTEMIC RADIATION AND TARGETED THERAPY
  6. INCIDENCE OF MULTIPLE PRIMARY MALIGNANT NEOPLASMS IN SIBERIA AND THE FAR EAST
  7. SENTINEL LYMPH NODE BIOPSY IN BREAST CANCER: ONGOING CONSIDERATIONS
  8. ROLE OF RADIATION THERAPY IN COMBINED AND MULTIMODAL TREATMENT OF T3-4N1-2-3M0-1-2 STAGE SKIN CANCER
  9. SURGICAL TREATMENT OF A GIANT RETROPERITONEAL LIPOMA: A CLINICAL CASE
  10. PREOPERATIVE PREDICTION OF WALL INVASION DEPTH OF PRIMARY TUMOR (PT) IN GASTRIC CANCER PATIENTS

◄ Back to the list